Establishing a joint venture company with Shanghai Liji to continuously empower the field of life sciences, in collaboration with GenBio
Pubtime：2023-04-30
View volume：216
On February 17, 2023, Heyuan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Heyuan Biotechnology") and Shanghai Liji Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Liji") signed a strategic cooperation agreement to jointly establish Heyuan Liji (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Heyuan Liji").
At the signing ceremony, Pan Oudong, Chairman of Heyuan Biotechnology, and Jia Guodong, General Manager, respectively expressed their strategic goals and future development visions for this cooperation. Wang Fujie, Vice General Manager of Heyuan Biotechnology, and Li Ruibiao, Founder of Shanghai Liji Biotechnology, successfully signed the cooperation agreement on site
Signed a strategic cooperation agreement with Yuan Liji
Heyuan Liji will undertake the well-known local "Liji Biology" reagent brand, focusing on the fields of life sciences and biotechnology, providing customers with technologically advanced, ready to use, easy-to-use, and economical products, covering molecular biology, immunology, biochemistry, and cell biology related reagents, kits, etc; And with the comprehensive empowerment of He Yuan Biotechnology, we will continuously enhance our innovative research and development capabilities for high-quality life science reagents, continue to provide high-quality products for the industry, and improve the efficiency of industry research and development.
“Li Ruibiao, founder of "Li Ji Biology," said, "Heyuan Biology is a leading listed company in the fields of gene research and gene therapy, integrating CRO and CDMO services. We are honored to jointly establish Heyuan Li Ji with Heyuan Biology. In the future, we hope that with Heyuan Biology's strong research and development capabilities, market development capabilities, and business layout capabilities, both parties can fully leverage their respective advantages, jointly serve the field of life sciences, and create more value
Wang Fujie, the deputy general manager of Heyuan Biotech, said: "Shanghai Liji is active in the localization development and innovation of life science reagents, and Heyuan Biotech attaches great importance to industrial integration development and local innovation. The establishment of Heyuan Liji is another step in the development of Heyuan Biotech's enabling industry, but also an important step in actively implementing the company's sustainable development strategy, exploring and layout the upstream and downstream synergy of the industrial chain. I wish Heyuan Liji can serve more customers with the efforts of both sides, and help the comprehensive strength of the domestic life science field and biopharmaceutical field to continue to improve."”
As a biotechnology company focused on the field of gene therapy, Heyuan Biotech is dedicated to providing CRO services such as gene therapy vector development and gene function research for basic research in gene therapy; Provide CDMO services for the research and development of gene therapy drugs, including recombinant viral vector drugs, oncolytic viruses, CAR-T cell therapy products, etc., including process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production. At present, we have served over 8000 research groups and 150 gene and cell therapy CDMO projects, assisting clients in obtaining 20 clinical trial approvals from multiple countries including China and the United States
With the mission of "empowering gene therapy and jointly safeguarding life and health", and with the research and production of gene therapy carriers as the core, Heyuan Biotechnology will adhere to customer-centric and professional service responsibility, build an internationally leading gene and cell therapy CXO group enterprise, accelerate the basic research, drug discovery, pharmaceutical research, clinical and commercialization process of gene therapy, promote the development of the gene therapy industry, and benefit human health!
Back
